We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Crowdfunding Opportunities in Medical


CELLMED Medical EIS
Cellmed is an immuno-oncology company that are developing treatments for ovarian cancer.  Their lead product PROCURE a dendritic cell vaccine and they are now looking to expand the treatment to target solid tumors.    
investment: £520,294 target: £500,000 pre-money valuation: £2,400,232
status: Stretch
More Information
104%
Bivictrix Therapeutics Limited Medical EIS SEIS
BiVictriX Therapeutics is a pharmaceutical company that are developing ADC's (Antibody Drug Conjugates) in the field of Oncology. They have invented a strategy that improves ADC selectivity towards cancer cells.
investment: £451,506 target: £430,000 pre-money valuation: £4,347,778
status: Extended
More Information
105%
PlaqueTec Medical EIS
Cardiovascular Disease is the leading cause of death in the UK, PlaqueTec have developed a Liquid Biopsy System, which allows cardiologists to gain further information from a patient's coronary artery and provide more effective treatment to those affected by the disease.
investment: £1,493,593 target: £2,100,058 pre-money valuation: £12,003,757
status: Active
More Information
71%
Pertinax Pharma Medical EIS
Infections can be reduced and patient quality of life can be improved by using antimicrobial wound care materials developed by Pertinax. In vitro studies have already been performed using the company's development across multiple applications.
investment: £616,916 target: £699,997 pre-money valuation: £1,799,992
status: Active
More Information
88%
Stablepharma Medical EIS
Stablepharma invents a disruptive solution that can eliminate waste and supply life-saving vaccines without refrigeration. It is a patented invention that allows vaccines to be stored for years and transported without refrigeration whilst adhering with the protocols established by the WHO. Its current project plan comprises the Tetanus vaccine processed by Clinical Trials in Humans. The success of this project will significantly enhance the value of the invention and allow it to set up a pilot scale production in the $36 bn human vaccine market.
investment: £233,540 target: £750,000 pre-money valuation: £20,000,000
status: Funded 9 days
to go
More Information
31%
Trecento Diagnostics Medical EIS SEIS
Trecento Diagnostics, with the help of a molecular testing system complete, they are now ready to launch a patent-pending collection device named HygieCatch®. It is a non-invasive, needle-free examination, in the vet practice providing DNA extraction from urine onsite with a report within 40 minutes of extraction of the sample. The company has identified partners in the UAE and US and is also in early-stage discussions with UK vet practices.  Furthermore, for the purpose of commercialisation of HygieCatch & the technology used, alongside addition of new tests including Lyme disease the company is planning to raise its capital.  
investment: £114,120 target: £250,000 pre-money valuation: £2,375,000
status: Funded 11 days
to go
More Information
46%
Cambridge Medical Technologies Limited Medical EIS
Cambridge Medical Technologies Limited (CMT) is a medical technology company which operates in the UK and the US. The company specialises in portable and wearable biosensors for medical applications. CMT’s products and subsystems provide clinical accuracy and real-time monitoring of certain blood biomarkers without the need for invasive blood tests. With its range of tech-enhanced medical products, CMT is thriving in the blood testing market, which is expected to reach $62.9bn by 2024.
investment: £1,750,160 target: £5,000,000
status: Active 18 days
to go
More Information
35%
Linear Diagnostics Medical EIS
Linear Diagnostics Limited (LDL) utilises a novel platform technology for assays in a wide range of sectors. With focus on simplicity, speed and sensitivity, LDL uses Linear Dichroism technology to develop a molecular diagnostic platform with the ability to detect multiple targets such as Chlamydia and Gonorrhoea, from a single sample in just 15 minutes. The platform is designed to offer diagnosis and treatment within a single clinical appointment. With the proceeds, this company will build a follow-on pipeline of POC products and explore the potential markers for head trauma.
investment: £61,000 target: £1,000,000
status: Active 3 days
to go
More Information
6%
Living With Medical EIS
A medical condition management platform allowing clinicians to create their own app to improve a patient's health whilst reducing costs. Living With develops smart apps specific to a person's condition, they currently have 3 products with another in the development stage. Their primary app, Squeezy, is the top paid medical app in the UK that helps patients with their pelvic floor exercises. Other apps, allow clinicians to monitor a patient's bowel and bladder health, as well as those with rheumatoid arthritis. These apps are already in use at multiple NHS Trusts and clinics. Funds are being raised to complete development of their apps to help those with lupus and lung cancer, in addition to further developing their existing products. The company aims to have thousands of apps that will be available worldwide to provide self-service treatment at any time. Living With is expecting to earn £1.07m in revenue by the end of March 2019.
investment: £103,000 target: £350,000
status: Active 4 days
to go
More Information
29%
Premium DC Surgical Supplies Limited Medical EIS SEIS
Reducing the cost of orthopaedic equipment by using compression screws and titanium maxiangle locking plates. DC Surgical Supplies have acquired an exclusive license with Palmer & Baker with the aim of helping the NHS cut the cost of purchasing regular-use equipment by as much as 35%. Their product is CE Certified and has been featured in The Telegraph.
investment: £99,000 target: £325,000 pre-money valuation: £487,500
status: Expired
More Information
30%
Premium OLBERON MEDICAL Medical EIS
Olberon is a UK based medical device innovations company seeking to raise funds for manufacturing and the sale of Vacuderm which is a device designed to assist with childrens cannulation procedure. Olberon Ltd has already got a strong portfolio of patented medical innovations and two medical devices which are market ready.
investment: £5,634 target: £100,000 pre-money valuation: £1,399,250
status: Expired
More Information
6%
Premium Arcis Biotechnology Medical EIS
Arcis Biotechnology provide nucleic acid sample preparation solutions. They have made the process of obtaining genetic material from biological samples less time consuming so it can be done in less than 3 minutes.
investment: £1,146,318 target: £999,999 pre-money valuation: £19,202,001
status: Expired
More Information
115%
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph